Groups such as Kyoto University have found candidates for therapeutic agents using iPS cells made from patients with Alzheimer's disease, and when they are administered to patients with Alzheimer's disease that develop due to genetic factors, the progression of symptoms tends to be suppressed. We announced the results of the clinical trial that allegedly had been seen.
This was revealed by a group such as Professor Haruhisa Inoue of the Center for iPS Cell Research and Application, Kyoto University, holding an online press conference.
The group uses iPS cells made from patient cells to search for drug candidates, a method called "iPS cell discovery," which uses a drug called "bromocriptine," which is used as a treatment for Parkinson's disease, to cause Alzheimer's disease. I found that it has the effect of reducing abnormal protein, which is considered to be one of the above.
Then, the group started a clinical trial to investigate the safety and efficacy of this drug in patients with "familial Alzheimer's disease" that develops due to genetic factors.
As a result, about 5 months after the start of administration,
▽ patients who received the fake drug had decreased cognitive function in 2 out of 3 patients, whereas
▽ patients who received this drug decreased. What I did was that only one in five people did.
Since the number of patients in the group is small, further research is needed to confirm the effect, and the progression of symptoms tends to be suppressed.
Professor Inoue said, "I found out that existing medicines may be used to overcome the disease. I would like to continue my research with the aim of putting it into practical use."